INCA036978 (INCA036978) Clinical Trials

1 recruiting trial·Incyte

INCA036978 is an investigational compound from Incyte in early-phase clinical evaluation for myeloproliferative neoplasms (MPNs), including myelofibrosis and polycythemia vera. The Phase 1 study is assessing safety and tolerability as monotherapy and in combination with standard-of-care agents, with the primary objective of establishing a recommended dose for further development. Incyte has an established franchise in MPNs through Jakafi (ruxolitinib) and is developing next-generation agents for patients with inadequate response or intolerance to existing JAK inhibitor therapy. The molecular target and full mechanism of action are not yet publicly disclosed.

Check your eligibility

Top recruiting

Recruiting INCA036978 trials

Ranked by phase and US site count. Filter by your biomarker profile →

Phase 122 US sites

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

Incyte Corporation

Cancer types studied

INCA036978 is under active investigation across multiple tumor types.

Blood Cancer — Myeloproliferative (MPN)

How OncoMatch helps you find INCA036978 trials

AI reads the protocol

OncoMatch reads the eligibility criteria for every INCA036978 trial and extracts structured requirements — biomarkers, stage, prior therapy — from protocol text.

Enter your results

Select your cancer type and mark your biomarker results. Your data never leaves your device. OncoMatch instantly filters to trials you may qualify for.

See your matches

Each trial shows which criteria you meet, which you don't, and which need more information. Bring the shortlist to your oncologist.

Find INCA036978 trials →